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Abstract
Biguanides such as metformin have previously been shown to antagonize
hepatic glucagon-stimulated cyclic AMP (cAMP) signalling independently
of AMP-activated protein kinase (AMPK) via direct inhibition of adenylate
cyclase by AMP. Here we show that incubation of hepatocytes with the
small-molecule AMPK activator 991 decreases glucagon-stimulated cAMP
accumulation, cAMP-dependent protein kinase (PKA) activity and downstream
PKA target phosphorylation. Moreover, incubation of hepatocytes with 991
increases the Vmax of cyclic nucleotide phosphodiesterase 4B (PDE4B) without
affecting intracellular adenine nucleotide concentrations. The effects of 991 to
decrease glucagon-stimulated cAMP concentrations and activate PDE4B are
lost in hepatocytes deleted for both catalytic subunits of AMPK. PDE4B is
phosphorylated by AMPK at three sites, and by site-directed mutagenesis,
Ser304 phosphorylation is important for activation. In conclusion, we provide a
new mechanism by which AMPK antagonizes h...
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Biguanides such as metformin have previously been shown to antagonize hepatic glucagon-
stimulated cyclic AMP (cAMP) signalling independently of AMP-activated protein kinase
(AMPK) via direct inhibition of adenylate cyclase by AMP. Here we show that incubation of
hepatocytes with the small-molecule AMPK activator 991 decreases glucagon-stimulated
cAMP accumulation, cAMP-dependent protein kinase (PKA) activity and downstream PKA
target phosphorylation. Moreover, incubation of hepatocytes with 991 increases the Vmax of
cyclic nucleotide phosphodiesterase 4B (PDE4B) without affecting intracellular adenine
nucleotide concentrations. The effects of 991 to decrease glucagon-stimulated cAMP
concentrations and activate PDE4B are lost in hepatocytes deleted for both catalytic subunits
of AMPK. PDE4B is phosphorylated by AMPK at three sites, and by site-directed muta-
genesis, Ser304 phosphorylation is important for activation. In conclusion, we provide a new
mechanism by which AMPK antagonizes hepatic glucagon signalling via phosphorylation-
induced PDE4B activation.
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O
ne of the short-term effects of glucagon in liver is to
increase glycogen breakdown and inhibit glycolysis1–3.
Glucagon provides the mechanism for switching the
metabolism of liver between the well-fed state and the starved
state, which comprises several phases. During the ﬁrst few hours
of starvation, glycogen reserves in the liver are mobilized to
maintain blood glucose, but during prolonged starvation,
hepatic gluconeogenesis prevails4. Glucagon action is mediated
by increased cyclic AMP (cAMP) via stimulation of adenylate
cyclase and subsequent activation of cAMP-dependent protein
kinase (PKA)5,6. Glycogenolysis is increased via phosphorylase
kinase activation downstream of PKA, which also inhibits
glycolysis by phosphorylating and inactivating liver
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1
isoenzyme), thereby lowering fructose-2,6-bisphosphate con-
centrations, and by phosphorylation-induced inactivation of
L-type pyruvate kinase. In the long-term, glucagon induces
the expression of key gluconeogenic enzymes, such as phospho-
enolpyruvate carboxykinase and glucose-6-phosphatase7,8, which
together with its short-term effects, accounts for the increase in
hepatic gluconeogenesis and glucose output in the fasted state9.
Type 2 diabetes is characterized by hyperglycaemia and, due to a
combination of insulin resistance and impaired b-cell function,
the liver excessively releases glucose into the blood. Also, elevated
plasma glucagon concentrations play a role in dysregulated
hepatic glucose production10. Metformin, the front-line drug
used worldwide for the treatment of diabetes, decreases hepatic
glucose production and activates AMP-activated protein kinase
(AMPK)11–16. However, whether AMPK and/or its upstream
kinase LKB1 is required for the inhibition of hepatic glucose
output by biguanides, such as metformin and phenformin, is
controversial17–22. Biguanides inhibit mitochondrial respiratory
chain complex I (ref. 23), resulting in a fall in ATP, and it was
proposed that the resulting increase in AMP in hepatocytes would
directly inhibit adenylate cyclase to abrogate glucagon-stimulated
increases in PKA activity independently of AMPK21. Recently, we
studied a small-molecule benzimidazole derivative that rapidly
and potently activates AMPK24, thereby stimulating glucose
uptake in skeletal muscle without increasing cellular AMP
levels25. In the present study, we used the same molecule,
referred to as 991, in primary mouse hepatocytes. We propose a
mechanism by which AMPK activation antagonizes glucagon
signalling by phosphorylating and activating the major hepatic
cyclic nucleotide phosphodiesterase (PDE) isoform PDE4B,
thereby lowering cAMP levels and decreasing PKA activation.
Results
Compound 991 decreases glucagon-stimulated PKA signalling.
Compound 991 (previously called ex229) is a potent small-
molecule AMPK activator that increases glucose uptake in
incubated rat and mouse skeletal muscles25. In primary mouse
hepatocytes, treatment with 991 before incubation with glucagon
dose-dependently decreased the glucagon-stimulated increase in
intracellular cAMP concentrations (Fig. 1a). Consistent with
effects on cAMP levels, 991 treatment antagonized increased
phosphorylation by glucagon of PKA downstream targets
glycogen phosphorylase (GP)26 at Ser14 and cAMP response
element-binding protein (CREB)27 at Ser133 (Fig. 1b–d,g).
Moreover, incubation with a single high dose of 991
antagonized the increases in cAMP levels and PKA activity in
response to increasing concentrations of glucagon (Fig. 1e,f). The
rise in cAMP levels in response to glucagon is transient (Fig. 2c)
and only a small increase in cAMP was needed (Fig. 1e) to elicit
PKA activation (Fig. 1f). In hepatocytes preincubated with 991,
increased GP activity (Fig. 1h) and increased GP Ser14
phosphorylation induced by glucagon (Fig. 1g) were also reduced.
AMPK activation leads to increased PDE activity. Direct
inhibition of adenylate cyclase by AMP has been proposed to
explain how biguanides reduce glucagon-stimulated cAMP
production in hepatocytes21. Indeed, in hepatocytes incubated
with phenformin, a reduction in intracellular ATP levels with
concomitant increases in AMP, ADP, AMP:ATP and ADP:ATP
ratios were observed (Fig. 2a). Also, treatment with 991 or
phenformin led to AMPK activation, which was unaffected by
glucagon (Fig. 2b). However, the effects of 991 to activate AMPK
and antagonize glucagon action in hepatocytes observed in our
study were not accompanied by changes in intracellular adenine
nucleotide concentrations, even at the maximal dose of 10 mM
(Fig. 2a). A time-course study indicated that there was no
signiﬁcant difference in the initial rate of cAMP production by
glucagon in hepatocytes preincubated with 991 (Fig. 2c),
suggesting that adenylate cyclase activity was not affected by
compound treatment. After 7min of incubation, glucagon-
stimulated cAMP levels decreased rapidly in cells preincubated
with 991, such that after 30min of incubation with glucagon,
cAMP concentrations were reduced by 80% (Fig. 2c). We
hypothesized therefore, that AMPK activation could lead to an
increase in PDE activity, thus lowering cAMP accumulation seen
in the presence of glucagon. Indeed, in extracts prepared from
hepatocytes incubated with 991, total PDE activity increased by
B50% in a dose-dependent manner, which correlated with
increased AMPK activity (Fig. 2d). Also, PDE activation after
treatment with 991 was comparable to that seen in hepatocytes
incubated with glucagon (Fig. 2e), which is known to activate
PDE as a negative feedback mechanism for cAMP signalling28.
PDE activation was also observed in hepatocytes incubated
with the AMPK activator 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR), but not signiﬁcantly with A769662, a
small-molecule AMPK activator that is not as effective as
compound 991, at least in skeletal muscle25. Interestingly,
treatment of hepatocytes with phenformin increased PDE
activity to similar levels to those observed with 991 (Fig. 2e),
and incubation with either phenformin or metformin led to dose-
dependent PDE activation, which correlated with increased
AMPK Thr172 phosphorylation (Supplementary Fig. 1).
Moreover, signiﬁcant increases in PDE activity were obtained
with submaximal doses of phenformin (100 mM) and metformin
(100–300 mM). To conﬁrm the implication of PDE activity in the
effect of 991 to lower cAMP, hepatocytes were incubated with the
pan-PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) with or
without 991, before addition of increasing concentrations of
glucagon (Fig. 2f). In the presence of IMBX, the effect of 991 to
decrease glucagon-induced cAMP accumulation was lost,
suggesting PDE dependence. In this experiment, the dose-
dependent increase in cAMP levels in response to glucagon was
much higher (Fig. 2f versus Fig. 1e), indicating that the PDE
inhibitor was effective.
Effects of compound 991 treatment are AMPK-dependent.
To test whether the effects of compound 991 treatment were
AMPK-dependent, primary hepatocytes were isolated from mice
in which the two catalytic subunits of AMPK had been speciﬁcally
deleted in liver (referred to as AMPK a1 /a2LS / ).
In hepatocytes from wild-type mice incubated with increasing
concentrations of glucagon, phosphorylation of ACC and AMPK
slightly increased, as seen by immunoblotting extracts (Fig. 3a),
even though AMPK activation by glucagon was not detected after
one hour of incubation (Fig. 2b). However, the effect of glucagon
to increase ACC phosphorylation was absent in hepatocytes from
AMPK a1 /a2LS / mice (Fig. 3a), suggesting that AMPK
mediates this effect. Moreover, the effect of incubation with 991
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to increase ACC phosphorylation in hepatocytes from control
mice was almost completely lost in hepatocytes from AMPK a1 /a2LS / mice and both total and pThr172-AMPK were
undetectable (Fig. 3a). In addition, the effects of 991 to abrogate
glucagon-stimulated cAMP accumulation (Fig. 3b) and PKA
activation (Fig. 3c) were abolished in incubations of hepatocytes
from AMPK a1 /a2LS / mice, indicating the requirement of
AMPK. Similar results were obtained in incubations of hepato-
cytes prepared from mice bearing a whole-body deletion of the
AMPK b1-subunit, which contributes towards providing a high-
afﬁnity binding site for compound 991 (ref. 24). There is almost
no AMPK activity in the liver of these mice (Woods and Carling,
unpublished data), and residual AMPK activity might have been
due to increased expression of the AMPK b2-subunit (Supple-
mentary Fig. 2B). In hepatocytes from AMPK b1-knockout
compared with wild-type mice, the effect of 991 to activate
AMPK and increase ACC phosphorylation was severely abro-
gated and the increase in Raptor (regulatory-associated protein of
mTOR) phosphorylation, another direct AMPK substrate, was
completely lost (Supplementary Fig. 2B). Importantly, in
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Figure 1 | Compound 991 activates AMPK in hepatocytes and decreases glucagon-stimulated PKA signalling. Primary mouse hepatocytes were
serum-starved overnight and incubated for 20min with the indicated concentrations of 991 or dimethylsulfoxide (DMSO) as vehicle before stimulation with
the indicated concentrations of glucagon for 15min. The cells were collected and lysed for the measurement of intracellular cAMP concentrations
by radioimmunoassay (a) or enzyme-linked immunosorbent assay (ELISA) (e), for immunoblotting phosphorylated and total proteins as indicated (b,d), for
PKA assay (f), for GP assay (h) and for quantiﬁcation of CREB and GP phosphorylation by immunoblotting (c,g). Values are means±s.e.m. for n¼4 (a,f–h)
or n¼ 5 (c,e) separate experiments, and in b and d representative blots are shown. Statistical analysis was by a paired Student’s t-test. *Indicates a
signiﬁcant difference (Po0.05) compared with control incubations with DMSO.
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hepatocytes from AMPK b1-knockout versus wild-type mice, the
effect of 991 to lower glucagon-stimulated cAMP accumulation
was markedly reduced (Supplementary Fig. 2A). Treatment of
hepatocytes from control mice with 991 increased PDE activity
in extracts by B50%, whereas in hepatocytes from AMPK
a1 /a2LS / mice the effect of 991 was lost, further conﬁrming
the requirement of AMPK. By contrast, incubation with glucagon
led to PDE activation in hepatocytes from both wild-type and
AMPK a1 /a2LS / mice (Fig. 3d).
PDE4 is the major isoenzyme activated by 991 in hepatocytes.
The expression of PDE isoenzymes in primary mouse hepatocytes
was investigated. Earlier studies suggested that the major
PDE isoenzymes expressed in liver are members of the
PDE3/4 subfamilies29–31. Real-time PCR revealed that
amongst these, the predominant PDE mRNA in primary mouse
hepatocytes was the PDE4B isoenzyme (Fig. 4a). The implication
of PDE isoenzymes in cAMP hydrolysis in hepatocytes was
assessed by the use of speciﬁc inhibitors in vitro. When
hepatocytes were preincubated with the PDE4-speciﬁc inhibitor
rolipram and 991 before addition of increasing concentrations of
glucagon, the cAMP-lowering effect of 991 was completely
abolished (Fig. 4b). Other compounds used were the PDE3-
speciﬁc inhibitor cilostamide and the pan-PDE inhibitor IBMX,
which, along with rolipram, were added to the assays for
measuring PDE activity in hepatocyte extracts. PDE activity in
control extracts was inhibited by about 70% by rolipram and by
over 90% by IBMX, but was not signiﬁcantly decreased by
cilostamide (Fig. 4c), conﬁrming that PDE4 is mainly responsible
for cAMP removal in primary mouse hepatocytes. Moreover,
PDE activation by 991 was not seen in the presence of rolipram
(or IBMX), but was still present when assays were performed in
the presence of cilostamide, suggesting that PDE4 was activated
in response to 991 treatment. PDE assays routinely contained
1 mM cAMP, but the extent of PDE activation in hepatocytes
incubated with 991 was the same when extracts were assayed with
a saturating concentration of cAMP (50 mM), indicating an effect
of 991 treatment on Vmax rather than KM (data not shown).
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Figure 2 | AMPK activation decreases cAMP levels by activating a PDE. Primary mouse hepatocytes were incubated for 1 h with DMSO as vehicle, 10mM
991, 500mM phenformin, 2mM AICAR, 100 mM A769662, 10 nM glucagon or with concentrations of 991 and glucagon as indicated for measurements of
intracellular adenine nucleotide concentrations (a), AMPK activity by immunoprecipitation using anti-AMPKa1 and anti-AMPKa2 antibodies (b,d) and total
PDE activity (d,e). In e, the 100% value for PDE activity in the DMSO-treated control condition was 6.4±0.7mU per mg of protein. In c, mouse
hepatocytes were incubated for 20min with 10mM 991 or DMSO as vehicle before incubation with 10 nM glucagon for ELISA measurements of cAMP
concentrations at the indicated times. In f, mouse hepatocytes were incubated for 20min with 10 mM 991 or DMSO as vehicle and 5mM pan-PDE inhibitor
IBMX before incubation with the indicated concentrations of glucagon for 15min and measurement of cAMP (ELISA method). Values are means±s.e.m. for
n¼ 3 (a–d), n¼ 5 (e) or n¼4 (f) separate experiments. Statistical analysis was by a paired Student’s t-test. *Indicates a signiﬁcant difference (Po0.05)
compared with control incubations with DMSO.
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Moreover, analysis of the effects of in vitro phosphorylation of
puriﬁed recombinant PDE4B by AMPK on the kinetic properties
of the enzyme revealed that Vmax increased approximately
twofold with no effect on KM (see below).
AMPK phosphorylates and activates mouse PDE4B in vitro. To
test whether PDE4B could be a direct AMPK substrate, we cloned
the 721-amino-acid-containing PDE4B isoenzyme (GenBank:
AF326555.1) from primary mouse hepatocyte total cDNA. The
recombinant protein was expressed in Escherichia coli as a glu-
tathione S-transferase (GST) fusion protein and puriﬁed before
removing the tag by speciﬁc proteolytic cleavage. Both bacterially
expressed recombinant activated AMPK and puriﬁed PKA cata-
lytic subunits phosphorylated PDE4B in the presence of [g-32P]
ATP in vitro (Fig. 5a), and using AMPK, a stoichiometry of
B1mol of phosphate incorporated per mol of PDE protein was
reached (Fig. 5c). With both AMPK and PKA, phosphorylation of
PDE4B in the presence of [g-32P] ATP was additive, suggesting
the presence of distinct phosphorylation sites. After maximal
phosphorylation by AMPK and [g-32P] ATP, followed by trypsin
digestion and peptide separation by HPLC, three AMPK phos-
phorylation sites were identiﬁed by liquid chromatography-cou-
pled tandem mass spectrometry (LC–MS/MS) in the major
radiolabelled peaks as Ser118, Ser125 and Ser304 (Fig. 5b). Ser118
is located in the upstream conserved regulatory region 1 of
PDE4B, and was also phosphorylated by PKA, in agreement with
previous reports of phosphorylation at this site leading to acti-
vation of long PDE4 isoforms32,33. Ser125 is also situated in
upstream conserved regulatory region 1, while Ser304
corresponds to Ser245 located in the catalytic domain of
PDE4D9 (ref. 34). The sequences surrounding Ser118, Ser125 and
Ser304 are well conserved in vertebrate PDE4 orthologues
(Supplementary Fig. 3A) and in the different mouse PDE4
isoforms (Supplementary Fig. 3B). When Ala residues were
introduced by site-directed mutagenesis to replace each Ser, the
stoichiometry of phosphorylation by AMPK decreased by
40–60% for the puriﬁed mutant recombinant proteins
compared with wild-type PDE4B (Fig. 5c and Supplementary
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Figure 3 | Compound 991 antagonizes glucagon signalling in an AMPK-dependent manner. Primary hepatocytes from wild-type mice or mice bearing a
liver-speciﬁc deletion of the two AMPK catalytic subunits (AMPK a1 / a2LS / ) were treated as described in the legends to Figs 1 and 2. The cells were
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Extracts were also prepared for the measurement of cAMP concentrations by ELISA (b), for PKA assay (c) and for PDE assay (d). Values are
means±s.e.m. for n¼ 3 (b–d) separate experiments, and in a representative immunoblots are shown. Statistical analysis was by a paired Student’s t-test.
*Indicates a signiﬁcant difference (Po0.05) compared with control incubations with DMSO or between the indicated conditions.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10856 ARTICLE
NATURE COMMUNICATIONS | 7:10856 | DOI: 10.1038/ncomms10856 | www.nature.com/naturecommunications 5
Fig. 4). In vitro phosphorylation of wild-type PDE4B by AMPK
increased the Vmax almost twofold without signiﬁcantly affecting
the KM for cAMP, which was 3–4 mM (Fig. 5d). When
recombinant PDE4B was incubated with ATP and AMPK or
PKA, or the two protein kinases in combination, phosphorylation
by AMPK or PKA led to a B50% increase in wild-type PDE4B
activity, and an additive effect (twofold activation) was observed
when both protein kinases were included together (Fig. 5e).
AMPK-induced PDE4B activation was completely abolished in
the S304A mutant, suggesting that phosphorylation at this site is
crucial for the increase in Vmax. PKA-induced PDE4B activation
was maintained in the S304A mutant, but was abolished in the
S118A mutant. Moreover, the additivity of PDE4B activation by
PKA and AMPK in combination was lost in the S304A mutant.
Interestingly, mutation of S118 or S304 to Ala substantially
decreased basal PDE activity of recombinant PDE4B compared
with the wild-type protein (Fig. 5e and legend), suggesting that
Ser118 and Ser304 could be important for catalysis or play
structural roles, as well as being important for phosphorylation-
induced PDE activation. Taken together, the ﬁndings suggest that
Ser304 of mouse PDE4B is probably the major activating
phosphorylation site for AMPK in vitro.
PDE4B is phosphorylated by AMPK in intact hepatocytes.
Finally we looked whether PDE4B could be phosphorylated by
AMPK in intact cells. PDE4B was immunoprecipitated from
primary mouse hepatocytes incubated with either 991 or phen-
formin, and extracts were subjected to immunoblotting with
phospho-speciﬁc antibodies. Commercial antibodies against
phosphorylation site peptide motifs for either PKA (to recognize
PDE4B phosphorylated at Ser118) or AMPK (to recognize
PDE4B phosphorylated at Ser125), as well as an anti-phospho-
peptide antibody raised against the sequence surrounding Ser304
that we generated ourselves were used. The speciﬁcities of the
anti-phospho antibodies were ﬁrst veriﬁed on recombinant
PDE4B phosphorylated by AMPK in vitro (Fig. 6a). Following
immunoprecipitation of endogenous PDE4B from intact hepa-
tocytes incubated with 991 or phenformin and immunoblotting,
phosphorylation increased at the three main sites we identiﬁed
(Fig. 6b), although some basal phosphorylation was seen in
control-incubated hepatocytes. In hepatocytes from wild-type
mice incubated with increasing concentrations of 991 or phen-
formin up to maximal doses, phosphorylation of AMPK, ACC
and Raptor was increased, and this increase was completely
abrogated or reduced in hepatocytes from AMPK a1 /a2LS /
mice (Fig. 6c). Again, although some basal PDE4B phosphor-
ylation at the activating site Ser304 was seen in untreated
hepatocytes, incubation of hepatocytes with the highest doses of
991 and phenformin led to signiﬁcant increases in PDE4B Ser304
phosphorylation, which were lost in hepatocytes from AMPK
a1 /a2LS / mice (Fig. 6c). Basal PDE4B Ser304 phosphor-
ylation, which was also apparent in hepatocytes lacking AMPK,
suggests that kinase(s) other than AMPK could phosphorylate
PDE4B. It is noteworthy that members of the AMPK-related
salt-inducible kinase (SIK) family were shown to be involved in
the regulation of hepatic gluconeogenesis35,36, and SIK1 was
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were serum-starved overnight, then total RNA was extracted for cDNA synthesis and real-time PCR using speciﬁc primers for the mouse PDE isoenzymes
indicated (a). In b, hepatocytes were incubated for 20min with 991 or with DMSO as vehicle control in the presence of the PDE4 inhibitor rolipram before
stimulation with indicated concentrations of glucagon for 15min. The cells were collected and lysed for the measurement of cAMP concentrations by ELISA.
In c, the cells were lysed after 1 h of treatment with 991 (10 mM) and/or glucagon (Glg, 10 nM), and extracts were assayed for total PDE activity in the
presence or absence of PDE inhibitors as indicated. The 100% value for PDE activity in extracts from control DMSO-treated cells was 2.7±0.7 mU per mg
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recently reported to activate mouse PDE4D in pancreatic b-cells
via phosphorylation of Ser136 (ref. 37), the residue corresponding
to Ser125 of PDE4B identiﬁed here.
Discussion
In the present study, we propose that hepatic AMPK activation
leads to phosphorylation-induced PDE4B activation, thereby
antagonizing the glucagon-stimulated rise in cAMP and PKA
signalling (summarized in Fig. 7). This proposal is based on
the following evidence: (1) treatment of hepatocytes with the
small-molecule AMPK activator 991 decreased glucagon-induced
increases in cAMP (Fig. 1a,e) by accelerating cAMP removal
(Fig. 2c) without affecting intracellular adenine nucleotide levels
(Fig. 2a); (2) compound 991 treatment led to a stable increase in
PDE activity (Fig. 2d,e), and inclusion of the PDE inhibitors
IBMX and rolipram in hepatocyte incubations abolished the
effect of 991 to reduce increases in cAMP levels in response
to glucagon (Figs 2f and 4b); (3) AMPK phosphorylated
puriﬁed PDE4B in vitro (Fig. 5a–c), resulting in an increase in
Vmax (Fig. 5d), and mutation of Ser304 to Ala abolished
phosphorylation-induced PDE activation by AMPK (Fig. 5e);
and (4) 991 treatment led to increased PDE4B Ser304
phosphorylation in intact hepatocytes (Fig. 6b). Importantly,
in hepatocytes from mice bearing a liver-speciﬁc deletion of the
two AMPK catalytic subunits, the effect of 991 treatment to
decrease cAMP levels and subsequent PKA activation in response
to glucagon was lost (Fig. 3b,c) along with PDE activation
(Fig. 3d) and increased PDE4B Ser304 phosphorylation (Fig. 6c).
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Interestingly, the AMPK phosphorylation sites in PDE4B we
identiﬁed correspond to recently described phosphorylation sites in
PDE4D9, and Ser245 of human PDE4D9 (Ser304 in PDE4B3) was
proposed as an activating site phosphorylated by an unknown
‘switch kinase’ activated by H2O2 (ref. 34). Also, in a
phosphoproteomics study38, PDE4C from hepatocytes was found
to be an AMPK substrate and the phosphorylation site identiﬁed
corresponds to Ser125 of PDE4B, present in all long PDE4
isoforms (Supplementary Fig. 3B). Moreover, phosphorylation sites
Ser118, Ser125 and Ser304 are well conserved in vertebrate PDE4B
orthologues (Supplementary Fig. 3A). Phosphorylation at Ser304 is
probably responsible for the increase in Vmax of PDE4B, since its
mutation to Ala abolished AMPK-induced PDE activation
(Fig. 5d). However, as reported for PDE4D9 (ref. 34), multi-site
phosphorylation of PDE4B might be necessary for full PDE
activation, and from our data we cannot rule out the involvement
of Ser118 and Ser125 phosphorylation in overall AMPK-induced
PDE4B activation. Phosphorylation-induced PDE4 activation by
AMPK might be of broad physiological relevance, since PDE4
(especially isoforms B and D) has a wide tissue distribution39.
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The concentrations of cAMP reached in our study in cultured
mouse hepatocytes incubated with glucagon (up to 20 pmol per
mg of protein in the absence of PDE inhibitors, Figs 1e,2c and 3b)
ﬁt well with values reported in the literature40–43. These values
were obtained using a commercial ELISA-based assay and were
much lower than those measured by radioimmunoassay
(B150 pmol per mg of protein, see for example Fig. 1a) or by
HPLC (B100 pmol per mg of protein, data not shown) when
the three methods were compared on the same sample. Such
differences are likely to be due to differences in sample
quenching. For radioimmunoassay, hepatocyte incubations
were immediately stopped with HCl. For HPLC, the cells were
immediately extracted with perchloric acid, whereas for
measurements by ELISA, the stopping mixture used for rapid
lysis of hepatocytes was a non-deproteinizing buffer containing
detergent and EDTA. Radioimmunoassay and HPLC would thus
give measurements of total cAMP levels, whereas ELISA would
provide measurements of "free" concentrations. However, effects
of 991 to decrease glucagon-stimulated increases in cAMP
were observed irrespective of the protocol used for cAMP
measurement. Increased PDE activity due to AMPK activation
would correspond to 5-10 pmol per min per mg of protein
(Figs 2d and 3d), which would be sufﬁcient to account for the
degradation of cAMP as measured by ELISA in 991-stimulated
hepatocytes incubated for 15min, with glucagon (Fig. 2c).
Whole-body deletions of PDE4B have been made in mice,
associated with inhibition of the lipopolysaccharide-stimulated
immune response of peripheral leukocytes44, increased Ca2þ
transients and contractility of cardiac myocytes45 and reduced
adiposity and high-fat-diet-induced adipose inﬂammation46.
PDE4B / mice were reported to be normal in terms of body
weight and growth rate, showing no obvious abnormalites44.
Also during starvation, serum glucose/insulin levels as well as
glucose/insulin tolerance were not altered in these mice46.
However, effects on liver metabolism were apparently not
investigated in these studies.
The decrease in glucagon-stimulated cAMP accumulation seen
in hepatocytes incubated with phenformin was proposed to be
due to direct inhibition of adenylate cyclase by AMP, with a
half-maximal effect at about 300 mM (ref. 21). In hepatocytes
incubated with 500 mM phenformin, AMP concentrations rose to
over 1mM (ref. 21), a value comparable to that of B2 nmol per
mg of protein seen here (Fig. 2a), which would correspond to
B0.5mM. However, free cytosolic AMP concentrations are much
less than total cellular concentrations because AMP is bound
by abundant proteins, such as glycogen phosphorylase,
adenylate kinase, 6-phosphofructo-1-kinase and fructose-1,6-
bisphosphatase47. The free AMP concentration in livers of
wild-type mice was calculated to be 3.9 nmol per g of wet
weight48, which would correspond to 7 mM AMP based on the
intracellular water space of perfused liver49. Therefore, even
under conditions of ATP depletion induced by phenformin, it is
unlikely that free AMP concentrations would rise to levels high
enough to inhibit adenylate cyclase. Although we cannot rule out
phenformin acting via direct inhibition of adenylate cyclase
by AMP, PDE activation could also explain the reduction in
glucagon-stimulated cAMP levels by biguanides previously
reported21 (see scheme, Fig. 7). Indeed, we show that
submaximal concentrations of 991, phenformin and metformin
activated PDE and the increase in PDE activity correlated with
AMPK activation due to compound treatment (Supplementary
Fig. 1).
In summary, by analogy with insulin signalling28, activation of
AMPK inhibits glucagon-stimulated cAMP accumulation by
activating a PDE. Interestingly, effects of metformin to lower
blood glucose levels are only seen in diabetic and not in
normal subjects50, consistent with increased circulating glucagon
concentrations in diabetic individuals, who presumably would
have elevated cAMP levels in liver. Our data suggest that AMPK
activation in the liver could be beneﬁcial by opposing short-term
glucagon action via PDE activation to reduce cAMP as a new
therapeutic strategy for the treatment of metabolic diseases
associated with dysregulated cAMP/PKA signalling, such as type
2 diabetes. It is also noteworthy that cAMP signalling is
important for the growth of certain cancers and that
suppression of negative feedback mechanisms occurs during
tumorigenesis51.
Methods
Reagents and materials. Compound 991 (previously referred to as ex229 (ref. 25)
from patent application WO2010036613, Merck Sharp & Dohme Corp., Metabasis
Therapeutics, Inc. Novel cyclic benzimidazole derivatives useful anti-diabetic
agents, 2010) was kindly provided by AstraZeneca Mo¨lndal, SE. Glucagon
(reconstituted GlucaGen) was from Novo Nordisk, phenformin and all other
reagents were from Sigma Aldrich. All cell culture reagents were from Life
Technologies. Oligonucleotides were from Eurogentec. [g-32P] ATP and [50 , 80-3H]
cAMP were from Perkin Elmer. Anti-total ACC (Merck Millipore, Catalogue
No. 04-322), anti-P-Ser79-ACC (Merck-Millipore, Catalogue No. 07-303),
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Merck-Millipore,
Catalogue No. MAB374), anti-total GP (Sigma, Catalogue No. HPA000962),
anti-total AMPK b1(R&D Systems, Catalogue No. AF2854) and anti-total AMPK
b2 (R&D Systems, Catalogue No. MAB3808), anti-PThr172-AMPK (T172)
(Cell Signaling Technologies, Catalogue No. 2535, anti-P-AMPK-substrate (Cell
Signaling Technologies, Catalogue No. 5759), anti-P-PKA-substrate (Cell Signaling
Technologies, Catalogue No. 9624), anti-total Raptor (Cell Signaling Technologies,
Catalogue No. 2280) and anti-P-Ser792-Raptor (Cell Signaling Technologies,
Catalogue No. 2083), anti-total CREB (Cell Signaling Technologies, Catalogue
No. 9197), anti-phospho-Ser133-CREB (Cell Signaling Technologies, Catalogue
No. 9198) and anti-total PDE4B (Origene, Catalogue No. TA503471) antibodies
were from the sources cited. Anti-P-Ser14-GP and anti-total AMPK (a1 and a2)
antibodies were kindly provided by Grahame Hardie (University of Dundee, UK).
A peptide surrounding Ser304 of mouse PDE4B (CKLMHSSSLNNTSI) was
synthesized with or without Ser304 phosphorylated and with a Cys (N-term) for
coupling to keyhole limpet haemocyanin (KLH) or bovine serum albumin (BSA)
(Imject maleimide-activated KLH/BSA kit, Thermo Fisher Scientiﬁc). The
KLH-coupled phosphopeptide was injected in rabbits (Thermo Fisher Scientiﬁc),
and the serum was afﬁnity puriﬁed on both BSA-coupled phosphopeptide and
non-phosphopeptide linked to CH-activated Sepharose 4B (GE Healthcare).
Catalytic subunits of PKA were puriﬁed from bovine heart as described
previously52. Recombinant bacterially expressed AMPK (a1b1g1) was activated
with recombinant bacterially expressed LKB1-MO25-STRAD complex52, both
Glucagon
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Metformin
(Phenformin)
AMPK
AMP
cAMP
Cyclase
991
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γ
β1
Downstream signalling
PDE4B
ATP
Figure 7 | How biguanides and compound 991 antagonize glucagon
signalling. Unlike biguanides, treatment with 991 activates AMPK without
increasing cellular AMP levels. Both biguanides and 991 activate the major
PDE 4B isoenzyme in hepatocytes in an AMPK-dependent manner.
Metformin and phenformin activate hepatic AMPK either directly or via a
rise in AMP, which could compete with ATP to inhibit adenylate cyclase.
Phosphorylation-induced activation of PDE4B by AMPK reduces glucagon-
stimulated cAMP accumulation. As a consequence, PKA activation by
glucagon and downstream signalling are decreased in hepatocytes
incubated with 991, the effect being AMPK-dependent.
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kindly provided by Dietbert Neumann (Maastricht University, Maastricht, NL).
pGEX6p1 vector was generously donated by Christopher Proud (South Australian
Health & Medical Research Institute, University of Adelaide, Australia). Synthetic
peptides were provided by Vincent Stroobant (LICR, Brussels, BE). Oligonucleotide
primers were synthetized by Integrated DNA Technologies.
Animals. Animal experiments were approved by the Universite´ catholique de
Louvain Brussels local ethics committee and conducted within the guidelines of
the European Convention for the Protection of Vertebrate Animals used for
Experimental and Other Scientiﬁc Purposes. Male C57BL/6 wild-type mice
(3–4 months old) were obtained from the local animal facility and maintained on a
12 h light/12 h dark cycle with free access to food and water. Liver-speciﬁc AMPK
a1/a2 knockout mice were generated53, and experiments on AMPK a1/a2 double
knockout and control mice were performed under the approval of the ethics
committee from University Paris Descartes (No. CEEA34.BV.157.12) and the
French authorization to experiment on vertebrates (No.75-886) in accordance with
European guidelines. The AMPKb1 knockout-mouse strain was generated by the
trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP
Repository (www.komp.org). These mice were used in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act (1986).
Primary mouse hepatocyte culture and incubation. Mice were anesthetized
(pentobarbital injection, i.p.) and livers were washed (with 50ml of Krebs-HEPES,
pH 7.65, supplemented with 0.5mM EDTA) and digested (with 50ml of
Krebs-HEPES, pH 7.65, containing 25mg of collagenase from Clostridium
hystolyticum and 0.5mM CaCl2) by perfusion through the inferior vena cava at a
rate of 5mlmin 1 as described18. The liver was removed and hepatocytes were
extracted in attachment medium (DMEM supplemented with 1 g l 1 glucose,
4mM glutamine, 1mM pyruvate, penicillin/streptomycin, 10% (v/v) FBS, 10 nM
insulin, 200 nM triiodothyronine (T3) and 500 nM dexamethasone). After ﬁltering
through a 100-mm mesh cell strainer (BD Falcon), cells were pelleted (50g 2min)
and resuspended in attachment medium for counting and seeding. Typically, cells
were distributed in six-well plates, 2ml per well containing 2.5 105 cells. After
attachment for 4 h, the cells were washed in PBS and incubated for 20 h in
overnight medium (DMEM containing 1 g l 1 glucose, 4mM glutamine, 1mM
pyruvate, penicillin/streptomycin and 100 nM dexamethasone). Before treatment,
the medium was replaced with fresh overnight medium. Unless otherwise stated,
the cells were incubated ﬁrst with 10 mM 991 (or 0.1% (v/v) DMSO, vehicle
controls) for 20min before treatment with the indicated concentrations of
glucagon (or PBS, vehicle controls) for 15min.
Cell lysis and immunoblotting. Following treatment in six-well plates, the
medium was removed and the cells were washed in cold PBS before lysis in
buffer containing 50mM HEPES, pH 7.5, 1mM EDTA, 1mM EGTA, 0.5% (v/v)
2-mercaptoethanol, 50mM NaF, 5mMNa4P2O7, 5mM sodium b-glycerophosphate,
1mM Na3VO3, 1mM dithiothreitol, 0.1% (w/v) Triton X-100 and Complete
protease inhibitor cocktail (150 ml per well). Extracts were centrifuged
(20,000g 5min at 4 C) and protein concentrations were measured. For
immunoprecipitation of PDE4B, 1mg of extract protein was incubated for 2 h
at 4 C with 50ml of protein G-Sepharose (GE Healthcare) previously coupled to
2 mg of anti-PDE4B antibody. For immunoblotting, 10 mg of sample protein or
eluted immunoprecipitated proteins were loaded on 7.5% (w/v) polyacrylamide
gels. Following SDS–PAGE, proteins were transferred to polyvinylidene diﬂuoride
membranes, which were then blocked in Tris-buffered saline (TBS) containing
0.1% (v/v) Tween and 5% (w/v) BSA. The membranes were incubated overnight at
4 C with the indicated primary antibodies diluted in blocking buffer, then washed
extensively before and after incubation for 1 h with horseradish peroxidase-con-
jugated secondary antibodies. Anti-total and anti-P-ACC, anti-total GP, anti-total
AMPK (b1 and b2), anti-P-AMPK, anti-P-AMPK-substrate, anti-P-PKA-substrate,
anti-total and anti-P-Raptor, anti-total and anti-P-CREB antibodies were used at a
dilution of 1:1,000. Anti-GAPDH and anti-total PDE4B antibodies were used at
dilutions of 1:30,000 and 1:500, respectively. Anti-P-PDE4B (S304), P-GP and anti-
total AMPK (a1 and a2) antibodies were used at dilutions of 1:1,000, 1:1,000 and
1:10,000, respectively. For incubation of membranes with the anti-P-PDE4B (S304)
antibody, the non-phosphopeptide used for antibody puriﬁcation was included at a
concentration of 10 mgml 1. Immunodetection was by ECL Classico substrate
(Merck Millipore). Immunoblots were quantiﬁed by densitometry using ImageJ
software. Uncropped scans of the blots used to generate the ﬁgures are shown in
Supplementary Fig. 5.
cAMP measurement. cAMP was measured using the ELISA-based cAMP XP
assay kit (Cell Signaling Technologies) according to the manufacturer’s protocol.
Following hepatocyte incubations in six-well plates, the cells were lysed in 100 ml of
kit buffer (20mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1%
(w/v) Triton, 2.5mM Na4P2O7, 1mM sodium b-glycerophosphate, 1mM Na3VO4,
1 mgml 1 leupeptin and 1mM phenylmethyl sulfonyl ﬂuoride). The samples were
diluted in lysis buffer in experiments with PDE inhibitors. After
centrifugation (20,000g 5min at 4 C), 50 ml aliquots of supernatant were taken
and added to 50 ml of horseradish peroxidase-cAMP kit solution (unknown
composition) for cAMP measurement. Quantiﬁcation was based on a linear
concentration curve, established with external cAMP standards. Alternatively,
1ml of 0.1M HCl was added to each well for cell lysis, and cAMP was measured in
the dried supernatant by radioimmunoassay using a home-made antibody after
sample acetylation54.
Enzyme assays. PKA activity in hepatocyte lysates was measured by phosphor-
ylation of a substrate peptide derived from rat heart 6-phosphofructo-2-kinase
(PFK-2, sequence PVRMRRNSFT) in the presence and absence of PKA inhibitor
peptide (PKI, sequence TYADFIASGRTGRRNAIHD). Lysates prepared for
immunoblotting (corresponding to 30 mg of protein) were assayed at 30 C in 30ml
of phosphorylation buffer containing 10mM MOPS, pH 7.0, 0.5mM EDTA,
10mM magnesium acetate, 5mM dithiothreitol, 100 mM substrate peptide and
100 mM [g-32P] ATP (speciﬁc radioactivity 1,000 c.p.m. pmol 1) with and without
10 mM PKI. After 5min, aliquots (20 ml) were spotted on P81 phosphocellulose
papers for the determination of 32P-incorporation. AMPK (a1 plus a2) activity
immunoprecipitated from hepatocyte lysates was measured as described55,56.
Puriﬁed PKA and recombinant activated AMPK were assayed in phosphorylation
buffer by measuring 32P incorporation from 0.1mM [g-32P] ATP (speciﬁc
radioactivity 1,000 c.p.m. pmol 1) into 200mM AMARA peptide
(AMARAASAAALRRR) for AMPK and 200mM the peptide PVRMRRNSFT for
PKA52. One unit of protein kinase activity corresponds to the amount that
catalyses the formation of 1 nmolmin 1 of product under the assay conditions.
GP activity was determined in the direction of glycogen synthesis as
described57. Lysates prepared for immunoblotting (corresponding to 100 mg of
protein) were assayed in 100ml of reaction mixture containing 25mM Tris-HCl,
pH 6.1, 50mM glucose 1-phosphate, 1% (w/v) puriﬁed oyster glycogen,
150mM NaF and 0.5mM caffeine for 20min at 30 C. Blanks for spontaneous
glucose 1-phosphate hydrolysis contained lysis buffer. Reactions were stopped by
adding 100ml of ice-cold 1.2M trichloroacetic acid, and the samples were
centrifuged (20,000g 5min at 4 C). Inorganic phosphate in the supernatant was
measured spectrophotometrically at 650 nm 30min after adding 20mM
8-anilinonaphthalene-1-sulfonic acid and 2mM ammonium molybdate in a ﬁnal
volume of 1ml.
PDE in aliquots of lysates prepared for immunoblotting (containing about 50 mg
of protein) or 0.5 mg of tag-removed recombinant PDE (see below) was assayed as
described58 for 10min at 30 C. The reaction mixture contained 40mM Tris-HCl,
pH 8.1, 0.5% (v/v) 2-mercaptoethanol, 5mM MgCl2, 0.1% (w/v) BSA and 1 mM
[50 , 80-3H] cAMP (speciﬁc radioactivity 400 d.p.m. pmol 1) in a ﬁnal volume of
500 ml. For determination of the effect of phosphorylation by AMPK on the kinetic
properties of recombinant PDE, cAMP concentrations were varied between 0.5 and
5 mM with a ﬁxed amount of [50, 80-3H] cAMP (1,000 d.p.m. ml 1). Blanks for
spontaneous cAMP hydrolysis contained the corresponding buffer. Reactions were
stopped by freezing in liquid nitrogen followed by thawing for 1min in boiling
water. The reaction product, radioactive AMP, was further hydrolysed with 0.2 U
of snake venom 50-nucleotidase for 10min at 30 C. Residual cAMP and AMP were
retained on 1ml Dowex-formate columns (0.5 10 cm, Biorad), and radioactive
adenosine in the ﬂow-through was collected after further elution with 2ml
of CH3OH for liquid scintillation counting. One unit of GP or PDE activity
corresponds to the amount that catalyses the formation of 1 mmolmin 1 of
product under the assay conditions.
Nucleotide measurements. Cells in six-well plates were lysed with ice-cold
50mM perchloric acid (500 ml per well). Following centrifugation (20,000g 10
min at 4 C) the supernatants were neutralized with B60ml of 1.1M NH4H2PO4.
The samples were then vacuum-dried and resuspended in 20 ml of water for
HPLC separation and quantiﬁcation of purine nucleotides as described59.
Real-time PCR. Total mRNA was extracted from untreated primary mouse
hepatocytes in six-well plates using 1ml per well of Trizol (Life Technologies)
reagent, according to the manufacturer’s instructions. RNA was quantiﬁed by
Nanodrop, and 500 ng was used for cDNA synthesis using the M-MLV RT kit (Life
Technologies) according to the manufacturer’s protocol. Reverse transcription
products were diluted 1:3 in nuclease-free water, and 1 ml was used for qPCR with
the Kapa Sybr Fast qPCR kit (Kapa Biosystems) in combination with the CFX96
Real Time PCR thermocycler (Biorad). The programme included 40 cycles at 95 C
for 10 s, 66 C for 10 s, 72 C for 30 s and a ﬁnal melting curve. PCR reactions were
carried out in a ﬁnal volume of 10 ml with 1 mM of each of the primers against the
different mouse PDE isoforms as described60.
Expression and puriﬁcation of mouse recombinant PDE4B. Total mRNA was
extracted and retro-transcribed as mentioned above. cDNA product (1 ml) was used
as a template for PCR, using Q5 High Fidelity DNA polymerase (New England
Biolabs) according to the manufacturer’s protocol and with the following
oligonucleotide primers: (F) 50-ggaaggatccATGACAGCAAAAAATTCTCC-30
and (R) 50-gctactcgagTTATGTGTCGATCGGAGACT-30 . PCR products were
gel-puriﬁed with Wizard SV gel and PCR clean-up system (Promega), and veriﬁed
by sequencing to conﬁrm a 721-amino-acid protein with 95% identity to human
PDE4B3. The sequence was cloned into the pGEX6p1 vector using the BamHI
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and XhoI restriction sites present in the primers. Site-directed mutagenesis was
carried out using the Herculase II Fusion DNA polymerase (Stratagen), with the
QuikChange (Agilent) protocol. GST-tagged PDE4B was expressed overnight at
18 C in BL21 E. coli cells induced with 0.5mM isopropylthiogalactoside. Bacteria
were then collected by centrifugation (5,000g 10min at 4 C), resuspended in
1/10 of the culture volume of ice-cold lysis buffer (50mM Tris-HCl, pH 7.5,
150mM NaCl, 0.1% (v/v) 2-mercaptoethanol, 0.01% (w/v) Brij 35, 0.5mM
phenylmethyl sulfonyl ﬂuoride, 0.5mM benzamidine Cl, 1 mgml 1 leupeptin and
1 mgml 1 aprotinin) and homogenized using a French press device. The lysate was
cleared by centrifugation (17,000g 20min at 4 C) and the supernatant was
passed through a 45-mm mesh ﬁlter (Millex-HA, Merck-Millipore) before loading
onto a GSH-Sepharose column (1 20 cm, GE Healthcare). After extensive
washing, the column was eluted with a 0–10mM gradient of GSH. Fractions were
subjected to SDS–PAGE followed by Coomassie Blue staining. Fractions containing
GST-PDE4B protein bands were pooled and concentrated using a 100-kD
ultraﬁltration unit (Amicon) while changing the buffer to enzyme storage buffer
(50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.1% (v/v) 2-mercaptoethanol and 10%
(v/v) glycerol). The GST tag was removed overnight at 4 C by incubation of 500mg
of fusion protein with 10U of HRV 3C protease (Sino Biological) according to the
manufacturer’s protocol.
In vitro phosphorylation. Recombinant PDE4B (1mg) was phosphorylated with
0.4U of puriﬁed activated recombinant bacterially expressed AMPK or puriﬁed
PKA catalytic subunits in 20 ml of kinase assay buffer (see PKA assay) containing
200mM AMP (for AMPK only) and 100 mM [g-32P] ATP (speciﬁc radioactivity
1,000 c.p.m. pmol 1). For kinetic studies, incubations contained non-radioactive
ATP at the same ﬁnal concentration. After 1 h at 30 C, the reaction was stopped
on ice, and 10ml of mixture was taken for further analysis. For kinetic studies,
samples were diluted ﬁvefold in enzyme storage buffer before PDE assay. For
measurements of the stoichiometry of phosphorylation, proteins were separated
by SDS–PAGE in 7.5% (w/v) polyacrylamide gels. Gels were stained using
PageBlue (Thermo Fisher Scientiﬁc) for protein band quantiﬁcation by Odyssey
infrared imaging. Bands were then excised from the gels for measurement of
32P-incorporation by liquid scintillation as described previously52.
Phosphorylation site identiﬁcation. Recombinant PDE (3mg) was phosphory-
lated as described above with 1U of activated AMPK in a ﬁnal volume of 60 ml for
1 h at 30 C. The reaction was stopped on ice, 20 mg of BSA was added as
carrier and proteins were precipitated with a ﬁnal concentration of 10% (w/v)
trichloroacetic acid for 45min on ice. Precipitated proteins were collected by
centrifugation (20,000g 10min at 4 C), washed in acetone, vacuum-dried and
resuspended in 50 ml of 50mM NH4HCO3, pH 8.0, for overnight digestion at 30 C
with trypsin. Peptides were separated by reverse-phase narrow-bore HPLC and
radioactive peaks were analysed by LC–MS/MS as described61. Multi-stage
activation was enabled for phosphate neutral loss of 98, 49 or 32.66 with respect to
the precursor m/z. Peak lists were generated and searched using SequestHT and
PhosphoRS 3.1 against a home-made protein database containing the human PDE
sequences obtained from Uniprot and the different mutants used in this study.
Phosphorylation site identiﬁcation was performed as described61 and validated
manually.
Statistical analysis. The results are expressed as means±s.e.m. of at least three
independent experiments. Unless otherwise stated, all two-group comparisons were
tested for statistically signiﬁcant differences using a paired two-sided Student’s
t-test, and Po0.05 was considered signiﬁcant.
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